Hexokinase 2 is a determinant of neuroblastoma metastasis

British Journal of Cancer

Volumn 114, Issue 7, 2016, Pages 759-766

  Botzer, Liat Edry ^a   Maman, Shelly ^a   Sagi Assif, Orit ^a   Meshel, Tsipi ^a   Nevo, Ido ^a   Yron, Ilana ^a   Witz, Isaac P ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

hexokinase 2; HIF 1 ; metastasis; neuroblastoma; Warburg effect

Indexed keywords

3 BROMOPYRUVATE; DEFEROXAMINE; DOXYCYCLINE; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PYRUVIC ACID DERIVATIVE; TETRACYCLINE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROBLASTOMA METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; XTT ASSAY; ADRENAL TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CELL CYCLE; CELL MOTION; DRUG SCREENING; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; WOUND HEALING;

ADRENAL GLAND NEOPLASMS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; HEXOKINASE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961219411     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.26     Document Type: Article

References (49)

1. Al jamal JA (2005) Involvement of porin N, N-dicyclohexylcarbodiimidereactive domain in hexokinase binding to the outer mitochondrial membrane. Protein J 24(1): 1-8.
2. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84(6): 1014-1020.
3. Balinsky D, Platz CE, Lewis JW (1984) Enzyme activities in normal, dysplastic, and cancerous human breast tissues. J Natl Cancer Inst 72(2): 217-224.
4. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1): 3751-3757.
5. Brahimi-Horn C, Pouyssegur J (2006) The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 93(8): E73-E80.
6. Buijs M, Vossen JA, Geschwind JFH, Ishimori T, Engles JM, Acha-Ngwodo O, Wahl RL, Vali M (2009) Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drug 27(2): 120-123.
7. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8): 563-572.
8. Chen Z, Zhang H, Lu WQ, Huang P (2009) Role of mitochondria-Associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787(5): 553-560.
9. Edry Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, Bäuerle T, Yron I, Witz IP (2011) Lung-residing metastatic and dormant neuroblastoma cells. Am J Pathol 179(1): 524-536.
10. Fardin P, Cornero A, Barla A, Mosci S, Acquaviva M, Rosasco L, Gambini C, Verri A, Varesio L (2010) Identification of multiple hypoxia signatures in neuroblastoma cell lines by l(1)-l(2) regularization and data reduction. J Biomed Biotechnol 2010: 878709.
11. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4): 679-695.
12. Haase VH (2010) The sweet side of HIF. Kidney Int 78(1): 10-13.
13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
14. Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, Park SC, Lee HS (2007) Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6(9): 2554-2562.
15. Klein-Goldberg A, Maman S, Witz IP (2014) The role played by the microenvironment in site-specific metastasis. Cancer Lett 352(1): 54-58.
16. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173(1): 83-91.
17. Levy A, Zage P, Akers L, Ghisoli M, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin A, Huang P, Zweidler-McKay P (2010) The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drug 30: 1-9.
18. Maman S, Edry-Botzer L, Sagi-Assif O, Meshel T, Yuan W, Lu W, Witz IP (2013) The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis. Int J Cancer 133(10): 2296-2306.
19. Maman S, Witz IP (2013) The metastatic microenvironment. In The Tumor Immunoenvironment, Shurin MR, Umansky V, Malyguine A (eds) Vol. XVI, pp 15-38. Springer: New York, NY
20. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9(9): 1084-1101.
21. Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Macias-Silva M, Sosa-Garrocho M, Moreno-Sanchez R (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273(9): 1975-1988.
22. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579): 2106-2120.
23. Mathupala SP, Heese C, Pedersen PL (1997) Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272(36): 22776-22780.
24. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer?s stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19(1): 17-24.
25. Mathupala SP, Rempel A, Pedersen PL (1995) Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 270(28): 16918-16925.
26. Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276(46): 43407-43412.
27. Mazzocca A, Carloni V (2009) The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 16(14): 1704-1717.
28. Modak S, Cheung NKV (2010) Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36(4): 307-317.
29. Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD (2009) Neuroblastoma: contemporary management. Arch Dis Child Educ Pract Ed 94(6): 177-185.
30. Nevo I, Oberthuer A, Botzer E, Sagi-Assif O, Maman S, Pasmanik-Chor M, Kariv N, Fischer M, Yron I, Witz IP (2010) Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. Int J Cancer 126(7): 1570-1581.
31. Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, Witz IP (2008) Generation and characterization of novel local and metastatic human neuroblastoma variants. Neoplasia 10(8): 816-827.
32. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4): 274-284.
33. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M (2006) Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24(31): 5070-5078.
34. Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [F-18]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 99(2): 260-266.
35. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555(1-3): 14-20.
36. Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H (2009) Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology 56(90): 355-360.
37. Peng Q, Zhou Q, Zhou J, Zhong D, Pan F, Liang H (2008a) Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. Cancer Biol Ther 7(7): 1128-1135.
38. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC (2008b) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19(4): 1045-1053.
39. Pietsch T, Gottert E, Meese E, Blin N, Feickert HJ, Riehm H, Kovacs G (1988) Characterization of a continuous cell line (MHH-NB-11) derived from advanced neuroblastoma. Anticancer Res 8(6): 1329-1333.
40. Polakis PG, Wilson JE (1982) Purification of highly bindable rat brain hexokinase by high performance liquid chromatography (HPLC) Biochem Biophys Res Commun 107(3): 937-943.
41. Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C, Auberger P, Pende M, Ricci JE (2010) Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29(11): 1641-1652.
42. Qin JZ, Xin H, Nickoloff BJ (2010) 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun 396(2): 495-500.
43. Sanchez-Arago M, Cuezva JM (2011) The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 9: 19.
44. Sethi N, Kang Y (2011) Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 11(10): 735-748.
45. Sheng H, Niu B, Sun H (2009) Metabolic targeting of cancers: from molecular mechanisms to therapeutic strategies. Curr Med Chem 16(13): 1561-1587.
46. Stubbs M, Bashford CL, Griffiths JR (2003) Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med 3(1): 49-59.
47. Subarsky P, Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20(3): 237-250.
48. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JFH (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): Identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18(1): 95-102.
49. Warburg O (1956) On the origin of cancer cells. Science 123(3191): 309-314.